LSPN North America: Method of treatment claims often challenged

Two thirds of biotech claims challenged in inter partes reviews are directed to methods of treatment, said Brendan O’Malley, partner at Fitzpatrick Cella Harper & Scinto, at a recent industry conference.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Penile implant maker’s $17m trade secret award unravels

20 April 2026 The maker of a cosmetic penile implant has suffered at the Federal Circuit, after a ruling said its trade secrets claims are not protectable while leaving a counterfeiting finding intact.

Americas

Appeals court eases Teva’s headache with reversal

17 April 2026 A ruling that invalidated three of Teva's headache treatment patents has been thrown out, sending a long-running case back to the lower court.

Americas

Cancer drug researcher hit with suit over mutation-targeting tools

16 April 2026 The Cambridge biotech is accused of infringing six patents covering technologies used to target drug-resistant cancer mutations.